Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel

Abstract Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real‐world data are limited. This real‐world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in a...

Full description

Bibliographic Details
Main Authors: Xavier Leleu, Eirini Katodritou, Thomas Kuehr, Evangelos Terpos, Jo Caers, Renato Zambello, Alessandra Brescianini, Tony Liang, Sally Wetten, Sorina N. Badelita
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:eJHaem
Subjects:
carfilzomib
multiple myeloma
proteasome inhibitor
real world
relapsed/refractory
Online Access:https://doi.org/10.1002/jha2.595

Similar Items

Similar Items